New Study Published In Lancet Respiratory Medicine Highlights QIAGEN N.V.'s Quantiferon-TB Potential To Predict Active Tuberculosis Risk In Infants

Published: Feb 16, 2017

HILDEN, Germany and GERMANTOWN, Maryland, February 16, 2017 /PRNewswire/ --

Results Suggest Benefits of Quantitative Screening of Young Children in Countries With High TB Burden

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that data published in The Lancet Respiratory Medicine journal shows screening with QuantiFERON-TB Gold (QFT) can detect latent tuberculosis (TB) infection in otherwise healthy young children and can predict which are likely to progress to the active stage of this life-threatening respiratory disease.

Results from the study of more than 2,500 young children in South Africa suggest that screening with the modern QuantiFERON-TB blood test could save lives in countries with a high TB burden by identifying those children most at risk of developing active disease. The study noted young children are particularly vulnerable to TB, with up to 20% of those infected by the bacteria developing the active TB disease.

"This study marks a true milestone. For the first time, there is a test that has demonstrated the potential to quantify the risk for young children to develop active tuberculosis. Researchers found that those with a QuantiFERON-TB test result above a certain threshold were far more likely than others to get sick with the active disease. TB is a terrible killer of children in high-burden countries, so early diagnosis and treatment could save many lives," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN.

Click here for full press release:{049783C5-174E-41FE-974D-1662A6DBD416}&lang=en

Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail:

Back to news